¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°, ±Ë¾ç À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°(2025-2033³â)
Peptic Ulcer Drugs Market by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker, Antacids, H2-Antagonists, Antibiotics, Ulcer protective), Ulcer Type, Distribution Channel, and Region 2025-2033
»óǰÄÚµå : 1635941
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 135 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,292,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,723,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,154,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦ ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 49¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 62¾ï ´Þ·¯¿¡ µµ´ÞÇÏ¿© 2025³âºÎÅÍ 2033³â±îÁö 2.51%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ¼ÒÈ­¼º±Ë¾çÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ ³ëÀÎ Àα¸ÀÇ Áõ°¡, ħ½ÀÀû ¼ö¼úº¸´Ù ´Ù¾çÇÑ ¾à¹° ¿ä¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚ ÁöÇâÀÇ º¯È­´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

¼ÒÈ­¼º±Ë¾ç(½ÊÀÌÁöÀå ±Ë¾ç)Àº À§, ¼ÒÀå, ½Äµµ ÇϺÎÀÇ Á¡¸·¿¡ Á¡Â÷ÀûÀ¸·Î ¹ß»ýÇÏ¿© °áÇÔÀ» À¯¹ßÇÏ´Â °³¹æ¼º ÅëÁõÀÔ´Ï´Ù. ¼ÒÈ­¼º±Ë¾çÀº º¸Åë ¿°Áõ, ¹æ»ç¼± Ä¡·á, ¾Æ½ºÇǸ°ÀÇ ÀæÀº º¹¿ëÀ̳ª ÁÖ»ç, Ç׿°ÁõÁ¦ Åõ¿© µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ¼ÒÈ­¼º±Ë¾çÀ» ¹æÄ¡Çϸé Áß»óºÎ ¹× »óü ÅëÁõ, üÁß °¨¼Ò, ³»ÃâÇ÷, ´ë·® ÃâÇ÷ µîÀ» À¯¹ßÇÏ¿© ÀÔ¿øÀÌ ÇÊ¿äÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ÇöÀç ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦(PPI), H2 ±æÇ×Á¦, Ç×»ýÁ¦, Ä®·ý À̿ °æÀïÇü »ê Â÷´ÜÁ¦(P-CAB), Á¦»êÁ¦, ±Ë¾ç º¸È£Á¦ µî ´Ù¾çÇÑ Á¾·ùÀÇ ¾à¹°·Î Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ÅëÁõÀ» ÁÙÀ̰í, Ä¡À¯ ½Ã°£À» ¿¬ÀåÇϸç, »ê ºÐºñ¸¦ ÃÖ¼ÒÈ­Çϰí, ¼¼±Õ °¨¿°¿¡ ´ëÇÑ ÀúÇ×·ÂÀ» Á¦°øÇϰí, ¼ÒÈ­¾×À¸·ÎºÎÅÍ À§¸¦ º¸È£ÇÕ´Ï´Ù. ±× °á°ú, ¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦´Â À§¿°, À§½Äµµ ¿ª·ùÁúȯ(GERD), ½ÊÀÌÁöÀå ±Ë¾ç Ä¡·á¸¦ À§ÇØ ÀÇ·á Àü¹®°¡µéÀÌ ³Î¸® »ç¿ëÇϰí ÀÖ½À´Ï´Ù.

¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦ ½ÃÀå µ¿Çâ:

¼ÒÈ­¼º±Ë¾çÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, °Ç°­¿¡ ÇØ·Î¿î »ýȰ½À°ü°ú À§¾ÏÀÇ Áõ°¡·Î ÀÎÇØ ¼ÒÈ­¼º±Ë¾ç ȯÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̴ ħ½ÀÀû ¼ö¼úº¸´Ù ´Ù¾çÇÑ ¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ºÇâÀÇ º¯È­¿Í ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ½ºÅ×·ÎÀ̵å°è Ç׿°ÁõÁ¦´Â ¼ö¼ú¿¡ ºñÇØ ´ú ħ½ÀÀûÀ̰í, °¡°ÝÀÌ Àú·ÅÇϸç, ÃâÇ÷À» ÁÙÀ̸鼭 ȸº¹À» ºü¸£°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦ÀÇ ½ÂÀÎÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ¾à¹°ÀÇ Á¦ÇüÈ­¸¦ À§ÇØ Á¤ºÎ°¡ Á¦¾àȸ»ç¿¡ ÅõÀÚÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÕº´ÁõÀ» ±Øº¹Çϱâ À§ÇÑ ½Å¾à °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ ÀÓ»ó½ÃÇèÀÇ ½Ç½Ã¿Í ½ÃÀå¿¡¼­ ÇöÀç ¾à¹°ÀÇ È¿°ú°¡ ³·´Ù´Â Á¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë È¿À²ÀûÀÎ ¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦ÀÇ ÀåÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í ´Ù¾çÇÑ À¯Åë ä³Î¿¡¼­ ½±°Ô ±¸ÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü ¹× ¹ýÀÇÇÐÀû Á¶ÀÛÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý º´¸® °Ë»ç ±â¼úÀÇ µîÀåµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦Ç°ÀÇ È¿´ÉÀ» Çâ»ó½Ã۱â À§ÇÑ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿°ú ¼ÒÈ­¼º±Ë¾ç Ä¡·á¿ë ÀϹÝÀǾàǰ(OTC) °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í °°Àº ´Ù¸¥ ¿äÀε鵵 ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ¼ÒÈ­¼º±Ë¾ç Ä¡·áÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : ±Ë¾ç À¯Çüº°

Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global peptic ulcer drugs market size reached USD 4.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.2 Billion by 2033, exhibiting a growth rate (CAGR) of 2.51% during 2025-2033. The increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various medications over invasive surgeries represent some of the key factors driving the market growth.

Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives. These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.

Peptic Ulcer Drugs Market Trends:

The increasing prevalence of peptic ulcers, especially amongst the geriatric population, represents one of the key factors driving the market growth. Moreover, unhealthy lifestyle habits and rising instances of stomach cancer, is resulting in the growing number of individuals suffering from peptic ulcers. This, along with the shifting consumer inclination towards various peptic ulcer-curing drugs over invasive surgeries, which, in turn, is contributing to the market growth. In line with this, as compared to surgical procedures, several steroidal anti-inflammatory medications are minimally invasive, more affordable, and enable faster recovery while ensuring reduced blood loss. Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth. The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.

Key Market Segmentation:

Product Type Insights:

Ulcer Type Insights:

Distribution Channel Insights:

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Peptic Ulcer Drugs Market

6 Market Breakup by Product Type

7 Market Breakup by Ulcer Type

8 Market Breakup by Distribution Channel

9 Market Breakup by Region

10 Drivers, Restraints, and Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â